Enteropathy with impaired membrane digestion and rebamipide

Cover Page

Cite item

Full Text

Abstract

The article describes enteropathy with membrane digestion disturbance (EMDD). At the basis of the disorder underlies a decrease of disaccharides and other membrane enzymes of small intestine mucous membrane (SIMM) activity. It can be caused by genetically determined and acquired enterocyte damage. EMDD clinical symptoms are presented with alimentary intolerances (stomach discomfort and pain, stool disturbances, and bloating). The diagnosis is based on SIMM enzymes biochemical study. Differential diagnosis should be performed between intestinal tract functional disorders, among which EMDD occurs frequently. The treatment is based at dieting with limitation of badly tolerated foods, the use of cytoprotector rebamipide that increases enzymes activity and intestinal antiseptics that inhibit bacteria growth in small intestine.

About the authors

Asfold I. Parfenov

Loginov Moscow Clinical Scientific Center

Email: asfold@mail.ru
D. Sci. (Med.), Prof. Moscow, Russia

Svetlana V. Bykova

Loginov Moscow Clinical Scientific Center

Cand. Sci. (Med.) Moscow, Russia

Elena A. Sabelnikova

Loginov Moscow Clinical Scientific Center

D. Sci. (Med.) Moscow, Russia

Nikolai I. Belostotskii

Loginov Moscow Clinical Scientific Center

D. Sci. (Med.) Moscow, Russia

Sergei G. Khomeriki

Loginov Moscow Clinical Scientific Center

D. Sci. (Med.), Prof. Moscow, Russia

Olga V. Akhmadullina

Loginov Moscow Clinical Scientific Center

Res. Assist. Moscow, Russia

M. Iu Zviaglova

Loginov Moscow Clinical Scientific Center

Res. Assist. Moscow, Russia

Saria R. Dbar

Loginov Moscow Clinical Scientific Center

Res. Assist. Moscow, Russia

References

  1. Ensari A, Мarsh M. Exploring the villus. Gastroenterol Hepatol Bed Bench 2018; 11 (3): 181-90.
  2. Helander H.F, Fändriks L. Surface area of the digestive tract-revisited. Scand J Gastroenterol 2014; 49 (6): 681-9.
  3. Torrente F, Ashwood P, Day R et al. Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol Psychiatry 2002; 7: 375-82.
  4. Williams B.L, Hornig M, Buie T et al. Impaired Carbohydrate Digestion and Transport and Mucosal Dysbiosis in the Intestines of Children with Autism and Gastrointestinal Disturbances. PLoS One 2011; 6 (9): e24585. DOI: 1371/journal.pone.0024585
  5. König J, Wells J, Cani P et al. Human Intestinal Barrier Function in Health and Disease. Clin Translation Gastroenterol 2016; 7: e196.
  6. https://meduniver.com/Medical/Physiology/funkcii_plotnix_kontaktov_kishechnika.html MedUniver
  7. Oshima T, Miwa H. Gastrointestinal mucosal barrier function and diseases. J Gastroenterol 2016; 51 (8): 768-78.
  8. Сафонова Е.А., Парфенов А.И., Мазо В.К. и др. Сравнительная оценка нарушений проницаемости кишечника при органических и функциональных заболеваниях. Рос. гастроэнтерологический журн. 2000; 4: 145-9. [Safonova E.A., Parfenov A.I., Mazo V.K. et al. Sravnitel'naia otsenka narushenii pronitsaemosti kishechnika pri organicheskikh i funktsional'nykh zabolevaniiakh. Ros. gastroenterologicheskii zhurn. 2000; 4: 145-9 (in Russian).]
  9. Bertiaux-Vandaële N. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am J Gastroenterol 2011; 106 (12): 2165-73.
  10. Martínez C et al. The Jejunum of Diarrhea-Predominant Irritable Bowel Syndrome Shows Molecular Alterations in the Tight Junction Signaling Pathway That Are Associated With Mucosal Pathobiology and Clinical Manifestations. Am J Gastroenterol 2012; 107 (5): 736-46.
  11. Farré R, Vicario M. Abnormal Barrier Function in Gastrointestinal Disorders. Hand Exp Pharmacol 2017; 239: 193-217.
  12. Парфенов А.И. Энтеропатия с нарушением мембранного пищеварения. М.: Медконгресс, 2019; 208 с. @@Parfenov A.I. Enteropathy with impaired membrane digestion. Moscow: Medkongress, 2019;208 p. (in Russian)
  13. Парфенов А.И., Ручкина И.Н., Атауллаханов Р.И., Белая О.Ф. Постинфекционный синдром раздраженного кишечника. Терапевтический архив. 2009; 81 (2): 39-45. @@Parfenov A.I., Ruchkina I.N., Ataullakhanov R.I., Belaia O.F. Postinfektsionnyi sindrom razdrazhennogo kishechnika. Therapeutic Archive. 2009; 81 (2): 39-45 (in Russian)
  14. Парфенов А.И., Ахмадуллина О.В., Сабельникова Е.А. и др. Дисахаридазная недостаточность и функциональные заболевания кишечника. Терапевтический архив. 2017; 89 (4): 45-52. @@Parfenov A.I., Akhmadullina O.V., Sabel'nikova E.A. et al. Disakharidaznaia nedostatochnost' i funktsional'nye zabolevaniia kishechnika.Therapeutic Archive. 2017; 89 (4): 45-52 (in Russian)
  15. Фролькис А.В. Энтеральная недостаточность. М.: Наука, 1989. @@Frol'kis A.V. Enteric insufficiency. Moscow: Nauka, 1989 (in Russian)
  16. Метельский С.Т. Транспортные процессы и мембранное пищеварение в слизистой оболочке тонкой кишки. Электрофизиологическая модель. М.: Анахарсис, 2007. @@Metel'skii S.T. Transport processes and membrane digestion in the mucous membrane of the small intestine. Electrophysiological model. Moscow: Anakharsis, 2007 (in Russian)
  17. Попов В.А. Мембранное пищеварение при хирургической патологии. М.: Медицина, 1982. [Popov V.A. Membrane digestion in surgical pathology. Moscow: Meditsina, 1982 (in Russian)
  18. Богомолов П.О., Еремина Е.Ю, Тимофеева Н.М. и др. Активность пищеварительных ферментов в биоптатах тонкой кишки при патологии ЖКТ. РЖГГК. 1996; 5 (3): 87-8. @@Bogomolov P.O., Eremina E.Iu, Timofeeva N.M. et al. Aktivnost' pishchevaritel'nykh fermentov v bioptatakh tonkoi kishki pri patologii ZhKT. RZhGGK. 1996; 5 (3): 87-8 (in Russian)
  19. Парфенов А.И., Сабельникова Е.А., Белостоцкий Н.И. и др. Активность карбогидраз как маркер восстановления слизистой оболочки тонкой кишки у больных целиакией. Терапевтический архив. 2015; 87 (2): 24-9. @@Parfenov A.I., Sabel'nikova E.A., Belostotskii N.I. et al. Aktivnost' karbogidraz kak marker vosstanovleniia slizistoi obolochki tonkoi kishki u bol'nykh tseliakiei. Therapeutic Archive. 2015; 87 (2): 24-9 (in Russian)
  20. Парфенов А.И., Белостоцкий Н.И., Хомерики, С.Г. и др. Ребамипид повышает активность дисахаридаз у больных энтеропатией с нарушением мембранного пищеварения. Пилотное исследование. Терапевтический архив. 2019; 91 (2): 25-31. @@Parfenov A.I., Belostotskii N.I., Khomeriki, S.G. et al. Rebamipid povyshaet aktivnost' disakharidaz u bol'nykh enteropatiei s narusheniem membrannogo pishchevareniia. Pilotnoe issledovanie. Therapeutic Archive. 2019; 91 (2): 25-31 (in Russian)
  21. Dahlqvist A. Specificity of the human intestinal disaccharidases and implications for hereditary disaccharide intolerance. J Clin Investig 1962; 41: 3-8.
  22. Trinder P. Depermination of glucosa in blood using glucosa oxidase with an alternative oxigen reception. J Ann Clin Biochem 1969; 6: 24-7.
  23. Парфенов А.И., Ахмадуллина О.В., Сабельникова Е.А. и др. Дисахаридазная недостаточность и функциональные заболевания кишечника. Терапевтический архив. 2017; 89 (4): 45-52. @@Parfenov A.I., Akhmadullina O.V., Sabel'nikova E.A. et al. Disakharidaznaia nedostatochnost' i funktsional'nye zabolevaniia kishechnika. Therapeutic Archive. 2017; 89 (4): 45-52 (in Russian)
  24. Staudacher H.M, Whelan K, Irving P.M, Lomer M.C. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutrition Dietet 2011; 24: 487-95. doi: 10.1111/j.1365-277X.2011.01162.x
  25. Парфенов А.И., Белостоцкий Н.И., Дбар С.Р. и др. Энтеропатия с нарушением мембранного пищеварения. Эффективная фармакотерапия. Гастроэнтерология. 2018; 16: 20-7. @@Parfenov A.I., Belostotskii N.I., Dbar S.R. et al. Enteropatiia s narusheniem membrannogo pishchevareniia. Effektivnaia farmakoterapiia. Gastroenterologiia. 2018; 16: 20-7 (in Russian)
  26. Arakawa T, Kobayashi K, Yoshikawa T et al. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 1998; 43: 5S-13S.
  27. Tarnawski A, Arakawa T, Kobayashi K. Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci 1998; 43 (Suppl.): 90S-98S.
  28. Tarnawski A.S, Chai J, Pai R, Chiou S.K. Rebamipide activates gene encoding angiogenic growth factors and COX2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci 2004; 49 (2): 202-9.
  29. Koyama N, Sasabe H, Miyamoto G. Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver. Xenobiotica 2002; 32: 573-86.
  30. Маев И.В., Казюлин А.Н. Новые возможности профилактики рака желудка. Терапевтический архив. 2017; 89 (4): 101-9. @@Maev I.V., Kaziulin A.N. Novye vozmozhnosti profilaktiki raka zheludka. Therapeutic Archive. 2017; 89 (4): 101-9 (in Russian)
  31. Makiyama K, Takeshima F, Kawasaki H, Zea-Iriarte W.L. Antiinflammatory effect of rebamipide enema on proctitis type ulcerative colitis: a novel therapeutic alternative. Am J Gastroenterol 2000; 95: 1838-9.
  32. Min H, Kim J, Lee S et al. Rebamipide prevents peripheral arthritis and intestinal inflammation by reciprocally regulating Th17/Treg cell imbalance in mice with curdlan-induced spondyloarthritis. J Transl Med 2016; 14: 190. doi: 10.1186/s12967-016-0942-5

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies